Bivalirudin is a direct thrombin inhibitor. As compared with a combination of heparin and a glycoprotein IIb/IIIa inhibitor, bivalirudin use resulted in less bleeding and lower 30-day mortality among patients undergoing PCI for acute myocardial infarction. However, bivalirudin was associated with a higher rate of acute stent thrombosis within 24 hours.
More...